122 related articles for article (PubMed ID: 9182081)
1. Hemodynamic and neurohormonal effects of flosequinan in patients with heart failure.
Isnard R; Lechat P; Pousset F; Carayon A; Kalotka H; Chikr H; Salloum J; Thomas D; Komajda M
Fundam Clin Pharmacol; 1997; 11(1):83-9. PubMed ID: 9182081
[TBL] [Abstract][Full Text] [Related]
2. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure.
Cavero PG; De Marco T; Kwasman M; Lau D; Liu M; Chatterjee K
J Am Coll Cardiol; 1992 Dec; 20(7):1542-8. PubMed ID: 1452928
[TBL] [Abstract][Full Text] [Related]
3. Flosequinan does not affect systemic and regional vascular responses to simulated orthostatic stress in healthy volunteers.
Duranteau J; Pussard E; Edouard A; Samii K; Berdeaux A; Giudicelli JF
Br J Clin Pharmacol; 1992 Sep; 34(3):207-14. PubMed ID: 1389945
[TBL] [Abstract][Full Text] [Related]
4. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
Kessler PD; Packer M; Medina N; Yushak M
J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
[TBL] [Abstract][Full Text] [Related]
5. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
[TBL] [Abstract][Full Text] [Related]
6. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
[TBL] [Abstract][Full Text] [Related]
7. The central haemodynamic effects of a single intravenous dose of flosequinan in patients with severe heart failure.
Markus H; Cowley AJ
Eur J Clin Pharmacol; 1991; 40(6):535-8. PubMed ID: 1884731
[TBL] [Abstract][Full Text] [Related]
8. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
Bartels GL; Remme WJ; Look MP; Kruijssen DA
J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
[TBL] [Abstract][Full Text] [Related]
9. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog.
Greenberg S; Touhey B
J Cardiovasc Pharmacol; 1990 Jun; 15(6):900-10. PubMed ID: 1694912
[TBL] [Abstract][Full Text] [Related]
10. Central and regional hemodynamic effects of flosequinan for congestive heart failure.
Haas GJ; Binkley PF; Carpenter JA; Leier CV
Am J Cardiol; 1989 Jun; 63(18):1354-9. PubMed ID: 2658526
[TBL] [Abstract][Full Text] [Related]
11. Influence of flosequinan on autonomic tone in congestive heart failure: implications for the mechanism of the positive chronotropic effect and survival influence of long-term vasodilator administration.
Binkley PF; Nunziata E; Cody RJ
Am Heart J; 1994 Dec; 128(6 Pt 1):1147-56. PubMed ID: 7985595
[TBL] [Abstract][Full Text] [Related]
12. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
[TBL] [Abstract][Full Text] [Related]
13. Flosequinan in chronic heart failure: how is exercise capacity improved?
Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
[TBL] [Abstract][Full Text] [Related]
14. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.
Falotico R; Haertlein BJ; Lakas-Weiss CS; Salata JJ; Tobia AJ
J Cardiovasc Pharmacol; 1989 Sep; 14(3):412-8. PubMed ID: 2476620
[TBL] [Abstract][Full Text] [Related]
15. The effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction.
Schneeweiss A; Wynne RD; Marmor A
Jpn Heart J; 1989 Sep; 30(5):627-34. PubMed ID: 2614925
[TBL] [Abstract][Full Text] [Related]
16. Chronic vasodilator therapy with flosequinan in congestive heart failure.
Haas GJ; Binkley PE; Leier CV
Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
[TBL] [Abstract][Full Text] [Related]
17. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
[TBL] [Abstract][Full Text] [Related]
18. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.
Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K
Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398
[TBL] [Abstract][Full Text] [Related]
19. Flosequinan induces hemodynamic improvement in heart failure complicating acute myocardial infarction.
Schneeweiss A; Marmor A; Wynne RD
Herz; 1988 Aug; 13(4):259-62. PubMed ID: 3169679
[TBL] [Abstract][Full Text] [Related]
20. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure.
Burstein S; Semigran MJ; Dec GW; Boucher CA; Fifer MA
J Am Coll Cardiol; 1992 Oct; 20(4):822-9. PubMed ID: 1527293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
